{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-164040","form_type":"8-K","ticker":"KLRA","cik":"0002096997","company_name":"Kailera Therapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.492233+00:00","generated_at":"2026-05-15T05:23:54.737561+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kailera Therapeutics closes IPO raising $718.8M; issues 44.9M shares at $16.00","bullets":["Closed IPO of 44,921,875 shares at $16.00 per share, including full exercise of underwriters' option for 5,859,375 additional shares.","Gross proceeds of $718.8 million before underwriting discounts and offering expenses.","Amended certificate of incorporation: authorized 800M shares of common stock and 10M shares of undesignated preferred stock.","Adopted classified board with staggered three-year terms; directors removable only for cause with two-thirds vote.","Amended bylaws to require advance notice for stockholder proposals and director nominations, and limit action by written consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-164040","json":"https://secwatch.observer/filing/0001193125-26-164040.json","markdown":"https://secwatch.observer/filing/0001193125-26-164040.md","text":"https://secwatch.observer/filing/0001193125-26-164040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/d137434d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:23:54.737561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4155bd13189cc843ab47d9dad5700997e7fa77f8","claim":"Kailera Therapeutics, Inc.: Amended and restated certificate of incorporation to fix authorized common stock, authorize undesignated preferred stock, establish classified board with staggered terms, require cause for director removal, require advance notice, eliminate written consent, and designate exclusive forums (effective 2026-04-20).","evidence_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","confidence":0.9},{"claim_id":"576b1f2b897b05910763691e7575a49fd2a16275","claim":"Kailera Therapeutics, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations and conform to charter amendments (effective 2026-04-20).","evidence_excerpt":"On April 20, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors, became effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","comparable_excerpt":"On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001703056-26-000078","ticker":"ADT","company_name":"ADT Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan","event_type":"other_material","sec_items":["5.02","5.03","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001703056-26-000078","json":"https://secwatch.observer/filing/0001703056-26-000078.json","markdown":"https://secwatch.observer/filing/0001703056-26-000078.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/0001703056-26-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/adt-20260504.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","comparable_excerpt":"On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/0001703056-26-000078-index.htm"}},{"accession":"0001213900-26-052459","ticker":"QLEP","company_name":"Quantum Leap Acquisition Corp","filed_at":"2026-05-06T23:59:59+00:00","headline":"Quantum Leap Acquisition Corp closes $200M SPAC IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-052459","json":"https://secwatch.observer/filing/0001213900-26-052459.json","markdown":"https://secwatch.observer/filing/0001213900-26-052459.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/0001213900-26-052459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/ea0289253-8k_quantum.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","comparable_excerpt":"In connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies. The Amended and Restated Memorandum and Articles of Association have an effective date of April 29, 2026, being the date on which the special resolution to adopt the Amended and Restated Memorandum and Articles of Association was passed.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/0001213900-26-052459-index.htm"}},{"accession":"0001829126-26-004565","ticker":"MCAH","company_name":"Mountain Crest Acquisition 6 Corp.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Mountain Crest Acquisition 6 Corp. closes $60M IPO; units start trading April 30","event_type":"other_material","sec_items":["1.01","3.02","5.03","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004565","json":"https://secwatch.observer/filing/0001829126-26-004565.json","markdown":"https://secwatch.observer/filing/0001829126-26-004565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/0001829126-26-004565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/mountaincrest6_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","comparable_excerpt":"On April 29, 2026, in connection with the IPO, the Company filed its Amended and Restated Memorandum and Articles of Association, as described in the Registration Statement, with the Registry of Corporate Affairs of British Virgin Islands.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/0001829126-26-004565-index.htm"}},{"accession":"0001193125-26-203988","ticker":"COAG","company_name":"Hemab Therapeutics Holdings, Inc.","filed_at":"2026-05-04T23:59:59+00:00","headline":"Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M","event_type":"other_material","sec_items":["5.03","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-203988","json":"https://secwatch.observer/filing/0001193125-26-203988.json","markdown":"https://secwatch.observer/filing/0001193125-26-203988.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/d149100d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","comparable_excerpt":"On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm"}},{"accession":"0001193125-26-201578","ticker":"RREV","company_name":"RRE Ventures Acquisition Corp.","filed_at":"2026-05-01T23:59:59+00:00","headline":"RRE Ventures Acquisition Corp. prices and closes $250M IPO; units begin trading on Nasdaq","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-201578","json":"https://secwatch.observer/filing/0001193125-26-201578.json","markdown":"https://secwatch.observer/filing/0001193125-26-201578.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2123969/000119312526201578/0001193125-26-201578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2123969/000119312526201578/d77496d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","comparable_excerpt":"On April 28, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended and Restated Memorandum and Articles of Association ”) with the Cayman Islands Registrar of Companies, which was effective on April 29, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2123969/000119312526201578/0001193125-26-201578-index.htm"}},{"accession":"0001213900-26-051018","ticker":"DMAA","company_name":"Drugs Made In America Acquisition Corp.","filed_at":"2026-05-01T23:59:59+00:00","headline":"SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M","event_type":"other_material","sec_items":["5.03","5.07","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-051018","json":"https://secwatch.observer/filing/0001213900-26-051018.json","markdown":"https://secwatch.observer/filing/0001213900-26-051018.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/0001213900-26-051018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/ea0288774-8k_drugs.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","comparable_excerpt":"to amend the Company’s Second Amended and Restated Memorandum and Articles of Association (the “ Existing Charter ”) by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the “ Extension Amendment ”) which reflects the extension of the date by which the Company must consummate a business combination (the “ Combination Period ”) up to twelve (12) times from April 29, 2026 (the “ Termination Date ”) to April 29, 2027, each by an additional one (1) month","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026051018/0001213900-26-051018-index.htm"}},{"accession":"0001649739-26-000020","ticker":"BAFN","company_name":"BayFirst Financial Corp.","filed_at":"2026-04-30T23:59:59+00:00","headline":"BayFirst raises $80M in PIPE, reports Q1 loss of $5.7M, names new bank CEO","event_type":"other_material","sec_items":["1.01","3.02","5.03","2.02","5.02","7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001649739-26-000020","json":"https://secwatch.observer/filing/0001649739-26-000020.json","markdown":"https://secwatch.observer/filing/0001649739-26-000020.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649739/000164973926000020/0001649739-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649739/000164973926000020/bafn-20260428.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm","comparable_excerpt":"On April 28, 2026, the Company filed Articles of Amendment to its Articles of Incorporation with the Florida Division of Corporations creating and authorizing 4,000 shares of Series D Preferred Stock and 4,000 shares of Series E Preferred Stock.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1649739/000164973926000020/0001649739-26-000020-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}